Michael Holinstat

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. ncbi Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis
    Michael Holinstat
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
    Arterioscler Thromb Vasc Biol 31:435-42. 2011
  2. ncbi Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation
    Jennifer Yeung
    Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mol Pharmacol 81:420-30. 2012
  3. ncbi 12-lipoxygenase: a potential target for novel anti-platelet therapeutics
    Jennifer Yeung
    Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA, USA
    Cardiovasc Hematol Agents Med Chem 9:154-64. 2011
  4. ncbi Newer agents in antiplatelet therapy: a review
    Jennifer Yeung
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    J Blood Med 3:33-42. 2012

Collaborators

Detail Information

Publications4

  1. ncbi Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis
    Michael Holinstat
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
    Arterioscler Thromb Vasc Biol 31:435-42. 2011
    ..We evaluated signaling via the human platelet thrombin receptors, protease-activated receptor (PAR) 1 and PAR4, to the activation of cPLA(2α), which provides a substrate for the biosynthesis of TxA(2) and 12-HETE...
  2. ncbi Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation
    Jennifer Yeung
    Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mol Pharmacol 81:420-30. 2012
    ..These studies support an essential role for PKC downstream of 12-LOX activation in human platelets and suggest 12-LOX as a possible target for antiplatelet therapy...
  3. ncbi 12-lipoxygenase: a potential target for novel anti-platelet therapeutics
    Jennifer Yeung
    Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA, USA
    Cardiovasc Hematol Agents Med Chem 9:154-64. 2011
    ....
  4. ncbi Newer agents in antiplatelet therapy: a review
    Jennifer Yeung
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    J Blood Med 3:33-42. 2012
    ....